ReviewDrug design, development and therapy2026
The Dual Role of IP-10/CXCL10 in Liver Injury: From Pathogenic Mediator to Clinical Biomarker and Therapeutic Target.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A complex interplay of immune and inflammatory mechanisms underlies liver injury, with the chemokine interferon-gamma-induced protein 10 (IP-10/CXCL10) playing a decisive role. Recent findings identify IP-10 as a key pathogenic mediator; by binding its receptor CXCR3, it directly recruits cytotoxic T lymphocytes and NK cells to the liver, promoting hepatocyte apoptosis and driving inflammation. This chemokine also activates hepatic stellate cells (HSCs), stimulating fibrogenesis and disease progression in conditions ranging from viral hepatitis to metabolic steatotic liver disease (MASLD) and cirrhosis. Consequently, IP-10 has emerged as a sensitive biomarker for liver inflammation and fibrosis. This review highlights these mechanistic insights, linking CXCL10's causal roles to its diagnostic, prognostic, and therapeutic potential. We examine its utility in early detection, risk stratification, and targeted therapies to modulate immune responses and reduce fibrosis. We also discuss innovative applications in personalized medicine and precision diagnostics that offer new opportunities to improve outcomes in viral hepatitis and other liver diseases. By integrating mechanistic understanding with clinical implications, this work clarifies the multifaceted role of CXCL10 and identifies future research directions to optimize its therapeutic and diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.